ArticleCytotechnology2025
IFITM1 promotes microglial polarization and NLRP3 inflammasome activation in ischemic stroke through up-regulating c-FOS.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hematopoietic Growth Factors Induce More Extensive Transcriptomic Remodeling in Cerebral Monocytes/Macrophages than in Microglia During the Chronic Phase of Traumatic Brain Injury.Molecular neurobiology · 2026Article
- NLRP3-mediated pyroptosis in cardiovascular disease: from molecular mechanisms to therapeutic targets.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microglial polarization and the NLRP3 inflammasome play critical roles in the pathology of ischemic stroke (IS). Regulation of microglial polarization towards M2 type has become a potential therapy approach for M2 type has become a potential therapy approach for treating IS. The current study demonstrated IFITM1 was markedly upregulated in microglia in the Distal middle cerebral artery (dMCAO) model. This research sought to assess the protective potential of IFITM1 knockdown in IS and to study its downstream regulatory mechanisms. The dMCAO mice model and oxygen-glucose deprivation/reoxygenation (OGD/R) BV2 cell model were constructed to imitate IS injury. The GSE148350 dataset was utilized to screen for differentially expressed genes in IS. Immunofluorescence, western blotting, and ELISA were utilized to evaluated activation level of NLRP3 inflammasome. RT-qPCR was applied to evaluated gene expression associated with the M1/M2 phenotypes and glycolysis of microglia. After treatment with dMCAO and OGD/R, IFITM1 expression was significantly upregulated. Knockdown of IFITM1 significantly inhibited M1 markers and promoted M2 markers of microglia. Additionally, knockdown of IFITM1 obviously inhibited the activation of the NLRP3 inflammasome and glycolysis. The expression of c-FOS was markedly raised following OGD/R, but was obviously inhibited by knockdown of IFITM1. Rescue experiments showed that knockdown of IFITM1 inhibited the NLRP3 inflammasome activation and M1 polarization of microglia by suppressing c-FOS expression. Knockdown of IFITM1 alleviated brain infarction, brain edema, and neurological damage in dMCAO mice. These results suggest that the absence of IFITM1 alleviates brain injury induced by dMCAO, inhibiting NLRP3 inflammasome activation and glycolysis of microglia through suppressing c-FOS expression. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-025-00832-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.